الفهرس | Only 14 pages are availabe for public view |
Abstract - 84- SUMMARY A group of 57 patient with bladder outflow obstruction due to B.P.H. were treated in 3 comparative study with finQstride(Proscar, M.K. 906), 5 - a- reductase inhibitor,S mg I day or prazocin 0.5 mg. twice daily starting by small dose and increasing it graduallyto lmg/day or placebo for 12 weeks. Subsequently 18 patients received finastride 5 mg I 24 hrs and 17 patient received .prazorcin 0.5 mg twice daily and 15 patient received placebo. ~* In the treated patients, P.S.A. level decline significantlywith finastride group only. * Total symptom score and peak flow rate and the amount of residual urine decrease significantly with finastride & prazosin group only but • placebo showed no significant improvement in these parameters Maximum flow rate increase by rates of 2 mll see in finastride group and about 1.5 mll sec. with prazosin after 12 weeks treatment. * Significant reduction in size of the prostate occurs only with finastride group. It decreased by about 30 gm after 12 weeks treatment with standard deviation 14.35. * With prazocin and placebo, no significant reduction of prostate size occurred. * After 12 week of drug free period, the size of the gland start to increase and the symptom score start to increase but by very small degrees (non significant). * The same occurred with prazoeine, due to release of inhibitory effect on a - adrenoceptors. T- 85- - This means that after stoppage of finastride therapy, the dilydrotestosterone level start to increase again and the gland start to increase in size with recurrence of symptoms. - So finastride shows some efficacy in treatment of BPH, with minimal toxicity but long periods may be necessary to achieve maximal effect. |